Phase 2 Breast Cancer Trial, Recruiting NCT05716516 Sponsor: Dartmouth-Hitchcock Medical Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05716516
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman who has gone through menopause and has been diagnosed with breast cancer that is driven by estrogen (called ER+ breast cancer).
  • Your cancer has either spread to other parts of the body or has come back in a nearby area, and it cannot be treated with the goal of a cure.
  • You have already received at least one hormone-based treatment (such as tamoxifen, aromatase inhibitors, or fulvestrant) for your advanced or spread cancer.

Who may not be able to join:

  • You are currently receiving other cancer treatments during the main treatment phase of the study, with two exceptions: a drug called trastuzumab may be allowed if you have a history of HER2+ breast cancer, and bone-strengthening medications (such as bisphosphonates or denosumab) are also permitted.
  • You have taken part in another experimental cancer treatment study within the last 3 weeks.
  • You have a known cancer spread to the brain or spinal cord, unless it has been stable for at least 3 months.
  • You have a history of a serious blood clot in a deep vein (such as in the leg).
  • You have a history of a blood clot in the lungs.
  • You have had a stroke in the past.
  • You have had a heart attack in the past.
  • You have had heart failure in the past.
  • You have had a previous different cancer that was not treated with the aim of a cure, or where the chance of it coming back is estimated at 30% or higher.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Muhammad Azfal, MD, Dartmouth-Hitchcock Medical Center

Phone: 1-800-639-6918

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 May 2023
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clinical Benefit Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov